Expansion of antibody research support and sales of antibodies and reagents

「Revenue from antibody research support rose to ¥40.270 million, up 65.4% year on year, due mainly to winning large-scale projects, an increase in the number of projects and the provision of services drawing on knowledge unique to a drug-discovery company. Revenue increased for the sixth consecutive fiscal period.」

「Revenue from antibody research support was ¥6.51 million, up 71.9% year on year. In May 2025, the company newly began providing antibody screening and generation services using a camel-derived VHH antibody library. Revenue from antibody and reagent sales was ¥54.453 million, down 2.1% year on year. In April 2025, the company launched an anti-Exatecan antibody for ADC research and development and an anti-GPR87 antibody for disease research. In October, it also began selling an anti-S1PR3 antibody for use in disease and metabolic research.」

「Revenue from antibody research support was ¥24.351 million, up 17.4% from the previous fiscal year and increasing for the fifth consecutive fiscal year, driven by orders for larger projects, an increase in the number of projects, and the provision of services drawing on the expertise distinctive to a drug discovery company. In May 2025, the company began providing antibody screening and generation services using a VHH antibody library as a new antibody research support service. Revenue from antibody and reagent sales was ¥96.024 million, up 20.5% from the previous fiscal year, and progressed steadily.」

「Revenue from antibody research support was ¥3.788 million, down 50.3% year on year, due to delivery dates for some projects falling into a different period. ③ Sales of antibodies and reagents: Revenue from antibody and reagent sales was ¥55.602 million, up 28.4% year on year, and progressed steadily. The company also launched an anti-MMAE antibody as a new product for ADC research and plans to provide a new service during the current fiscal year.」

「Revenue from antibody research support improved substantially to ¥20.735 million, up 72.2% from the previous fiscal year, driven by orders for larger projects, an increase in the number of projects, and the provision of services drawing on the expertise distinctive to a drug discovery company.」

「Revenue from antibody research support was ¥9.221 million, up 110.5% year on year, continuing the improvement trend seen in the second quarter. ③ Sales of antibodies and reagents: Revenue from antibody and reagent sales was ¥62.464 million, down 4.3% year on year, and progressed almost in line with plan. The company announced new products in October 2023 and will continue expanding its product lineup. It is also continuing the joint development of a rapid PTX3 measurement kit with Wakunaga Pharmaceutical Co., Ltd.」

「Revenue from antibody research support was ¥7.622 million, up 129.6% year on year. In September, the company began providing a single-cell picking service as a new antibody research support service using single-cell cloning technology for use in academic and corporate research and development. ③ Sales of antibodies and reagents: Revenue from antibody and reagent sales was ¥43.315 million, down 2.0% year on year, and progressed almost in line with plan. The company also announced new products in October and will continue expanding its product lineup.」

「Revenue from antibody research support was ¥2.182 million despite delays in some deliveries, an improvement from the same period of the previous year, when there were no sales. ③ Sales of antibodies and reagents: Revenue from antibody and reagent sales was ¥22.594 million, down 11.0% year on year, but the company expects to achieve its full-year sales plan.」

「Revenue from antibody research support was ¥12.039 million, up 47.2% from the previous fiscal year. Sales of research-use antibodies and reagents remained on a recovery trend, and overseas transactions recovered to pre-COVID-19 levels. Revenue was ¥82.161 million, up 28.9% from the previous fiscal year.」

「Revenue from antibody research support for the cumulative third quarter was ¥4.38 million, a substantial improvement from ¥85 thousand in the same period of the previous year, which was affected by the spread of COVID-19. ③ Sales of antibodies and reagents: Revenue from antibody and reagent sales for the cumulative third quarter was ¥65.288 million, up 33.1% year on year, and progressed steadily.」

「Revenue from antibody research support for the cumulative second quarter amounted to ¥3.320 million.」

「There was no revenue during the cumulative first quarter, but the Company received orders for multiple research support services. ③ Antibody and reagent sales: Antibody and reagent sales progressed steadily. The Company is also developing a rapid PTX3 measurement kit jointly with Wakunaga Pharmaceutical Co., Ltd.」

「In the current fiscal year, revenue increased from the previous fiscal year because antibody research support for universities increased. Revenue from both antibody and reagent sales and antibody research support increased from the previous fiscal year, and the plan was achieved.」

「Revenue from antibody research support for the cumulative third quarter amounted to ¥85 thousand, down 97.4% year on year, and remained sluggish, although revenue is expected to be recognized from multiple projects in the fourth quarter. ② Antibody and reagent sales: Revenue from antibody and reagent sales for the cumulative third quarter amounted to ¥49.048 million, up 4.8% year on year, and progressed almost in line with the plan.」

「Revenue from antibody and reagent sales for the cumulative second quarter amounted to ¥29.352 million, progressing almost in line with the plan.」

「Sales of research-use antibodies progressed almost in line with the plan.」

「To increase revenue from contract research, the Company will promote new contract research projects from universities, corporate research institutions and others. In addition, because researchers' antibody selection is influenced by published evidence of use in academic papers, the Company will seek to increase sales of antibodies and reagents by posting examples of its antibodies being cited in papers on its website.」